Mobile website
Basic Research
Inhibitory effects of antistathmin monoclonal antibody combined with paclitaxel against proliferation of human hepatocellular carcinoma cell line HepG2
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To investigate the inhibitory effects of antistathmin monoclonal antibody combined paclitaxel on the proliferation of human hepatocellular carcinoma cell lines HepG2.Methods: HepG2 cells were treated with antistathmin monoclonal antibody, paclitaxel or their combinations; untreated cells served as control. 24, 48, 72, and 96 h after exposure, the numbers and morphology of cells in different groups were observed under inverted microscope. Proliferation and apoptosis of HepG2 cells in different groups were studied by MTT and Annexin V/PI staining, respectively. Results: The numbers of HepG2 cells were decreased in all treated groups; and the cells in these groups showed morphological changes: some with round shape, some with nuclear chromatin condensation; but HepG2 cells in the control group did not show abnormal morphology. Antistathmin monoclonal antibody, paclitaxe alone or in combinations dosedependently inhibited the proliferation of HepG2 cells, and the inhibitory rate in the combination group was significantly higher than those in the two single drug groups (P<0.05), suggesting a synergistic effect between the two drugs (P<0.05). Antistathmin monoclonal antibody, paclitaxe alone or in combinations induced apoptosis of HepG2 cells, and the apoptosis in the combination group was higher than those in the two single drug groups (P<0.05). Conclusion: Antistathmin monoclonal antibody, paclitaxe alone or in combination can inhibit proliferation and induce apoptosis of HepG2 cells, and a synergistic effect is observed between antistathmin monoclonal antibody and paclitaxe.
Keywords:
Project Supported:
Supported by the National High Technology Research and Development Program of China (863 Program)（No.2006AA02A311）
Clc Number:
